GlassScriptPhysician profile
Tuyen Tran
NPI 1659010957
$736.04
in general payments reported to CMS, 2019-2025
14 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $282 · 2023: $190 · 2024: $132 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $235.20 | 2022-2024 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.45 | 2022-2025 | |
| Novo Nordisk INC | $82.37 | 2025 | Wegovy |
| Abbvie INC. | $54.54 | 2023-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $43.80 | 2022-2024 | Reblozyl, Welireg, Keytruda |
| Axsome Therapeutics, INC. | $29.60 | 2022 | |
| Gilead Sciences, INC. | $22.20 | 2023 | Epclusa |
| Eisai INC. | $19.69 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $17.30 | 2023 | Inpefa |
| Lilly USA, LLC | $16.95 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.56 | 2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.35 | 2022 | |
| Glaxosmithkline, LLC. | $14.12 | 2025 | Arexvy, Shingrix, Penmenvy |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuyen Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.